Chan Alexander, Tsourkas Andrew
Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
BME Front. 2024 Jan 25;5:0035. doi: 10.34133/bmef.0035. eCollection 2024.
Protein biologics are powerful therapeutic agents with diverse inhibitory and enzymatic functions. However, their clinical use has been limited to extracellular applications due to their inability to cross plasma membranes. Overcoming this physiological barrier would unlock the potential of protein drugs for the treatment of many intractable diseases. In this review, we highlight progress made toward achieving cytosolic delivery of recombinant proteins. We start by first considering intracellular protein delivery as a drug modality compared to existing Food and Drug Administration-approved drug modalities. Then, we summarize strategies that have been reported to achieve protein internalization. These techniques can be broadly classified into 3 categories: physical methods, direct protein engineering, and nanocarrier-mediated delivery. Finally, we highlight existing challenges for cytosolic protein delivery and offer an outlook for future advances.
蛋白质生物制品是具有多种抑制和酶促功能的强大治疗剂。然而,由于它们无法穿过质膜,其临床应用仅限于细胞外应用。克服这一生理障碍将释放蛋白质药物治疗许多难治性疾病的潜力。在这篇综述中,我们重点介绍了在实现重组蛋白胞质递送方面取得的进展。我们首先将细胞内蛋白质递送作为一种药物模式与现有的美国食品药品监督管理局批准的药物模式进行比较。然后,我们总结了已报道的实现蛋白质内化的策略。这些技术可大致分为三类:物理方法、直接蛋白质工程和纳米载体介导的递送。最后,我们强调了胞质蛋白质递送目前存在的挑战,并对未来的进展进行了展望。